ライフサイエンスコーパス: chimeric receptor

1 complementation assay to screen against this chimeric receptor.

2 yrosines contributed to the function of this chimeric receptor.

3 toreactive T cells by a MBP89-101-IA(s)-zeta chimeric receptor.

4 e specificities not directly targeted by the chimeric receptor.

5 sts demonstrated greater EC50 values for the chimeric receptor.

6 to compete for (33)P-relaxin binding to the chimeric receptor.

7 tations of signaling exclusively through the chimeric receptor.

8 in the sustained signaling activity of this chimeric receptor.

9 the activation of PLCgamma mediated by this chimeric receptor.

10 tracytoplasmic portion of the IL-2R via this chimeric receptor.

11 CCR5 inhibitor binding site using CCR5/CCR2b chimeric receptors.

12 ell receptor and tumor targets through their chimeric receptors.

13 domain is critical for proliferation of the chimeric receptors.

14 based reporter assay employing LXRalpha-GAL4 chimeric receptors.

15 nic receptors was evaluated at wild-type and chimeric receptors.

16 nd antitumor activity mediated through their chimeric receptors.

17 R/syntrophin interaction was confirmed using chimeric receptors.

18 ce expression and abrogated signaling of the chimeric receptors.

19 t1 fibroblasts transfected with EGFR or HER2 chimeric receptors activated by synthetic ligands withou

20 Testing of these chimeric receptors against a battery of AIP analogs loca

21 he melatonin-related receptor, the resultant chimeric receptors all displayed specific 2-[(125)I]iodo

22 isulfide-mediated oligomerization of another chimeric receptor, alpha zetazeta, enhances signaling.

23 Chimeric receptor analyses raise the possibility that th

24 The combination of the chimeric receptor and GFP-Smad2 makes it possible to fol

25 Chimeric receptor and molecular modeling studies also we

26 D8(+) T cells were engineered to express the chimeric receptor and were costimulated ex vivo with bea

27 se differences was investigated by preparing chimeric receptors and by site-directed mutagenesis.

28 18 inhibition of cells expressing CXCR4/CCR5 chimeric receptors and CCR5 with a truncated N terminus

29 esponsible for this selectivity, a series of chimeric receptors and mutant receptors was constructed

30 its ligand-selective activation, we assayed chimeric receptors and receptor variants containing subs

31 d this dichotomy through the construction of chimeric receptors and site-directed mutagenesis in orde

32 Chimeric receptors and structurally guided amino acid su

33 eptor is tyrosine phosphorylated through the chimeric receptors and the endogenous IL-6 and OSM recep

34 gastrin-releasing peptide (GRPR), we used a chimeric receptor approach and a site-directed mutagenes

35 n and therefore validated the utility of the chimeric receptor approach for signaling pathway identif

36 Here we have used a chimeric receptor approach in which the extracellular do

37 To address this issue, we developed a chimeric receptor approach that permits a structure/func

38 To investigate the basis for this, we used a chimeric receptor approach to make both GRPR loss of aff

39 A chimeric receptor approach was utilized to identify key

40 Nevertheless, using a chimeric receptor approach, we previously found that RYK

41 procally, reporter cells with a CD3zeta-LLT1 chimeric receptor are stimulated by NKR-P1A.

42 Although chimeric receptors are not pathogenic per se, the freque

43 specifically validate humanized MBP-DR2-zeta chimeric receptors as a potential therapeutic in MS.

44 scence microscopy revealed that internalized chimeric receptors, as identified with fluorescent ligan

45 binding specificity of alpha(L)beta(2), the chimeric receptor became competent to support cell migra

46 This chimeric receptor became localized to detergent-insolubl

47 All but one chimeric receptor bound IL-8 and mediated signal transdu

48 The chimeric receptor bound radiolabeled TGF-beta and could

49 These chimeric receptors bound CPV capsids and mediated uptake

50 tion induces tyrosine phosphorylation of the chimeric receptor but does not enhance its binding to SH

51 ecific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.

52 Furthermore, cells expressing the chimeric receptor, but not alpha(L)beta(2), were able to

53 demonstrate activation of a TREM-2A/CD3zeta chimeric receptor by both bacteria and dextran sulfate.

54 ty of a constitutively active RARgamma-VP-16 chimeric receptor by the inverse agonist AGN193109 requi

55 Engagement of the chimeric receptor by the TCR of autoreactive T cells act

56 l domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain

57 We designed chimeric receptors by switching the N terminus and 3 ext

58 Here we describe the use of chimeric receptors called signaling and antigen-presenti

59 igand for CXCR4; namely CXCL12, binds to the chimeric receptor CCR5(QTY) (7TM)-CXCR4 (N terminus+3 EC

60 In THP-1 cells expressing a chimeric receptor CD4-TLR4, which triggers constitutive

61 B cell lines expressing the human CD40-LMP1 chimeric receptor, CD40- and LMP1-mediated NF-kappaB and

62 Chimeric receptor chains of the gammaC tail fused to the

63 rm of DEP-1 formed a stable complex with the chimeric receptor colony stimulating factor 1 (CSF)-Met

64 t effective of these interventions created a chimeric receptor combining the ligand-binding domain of

65 residue within the ICD of alpha3GlyRs and of chimeric receptors combining bacterial GLIC and alpha3Gl

66 myoblast proliferation in situ, we created a chimeric receptor composed of a modified FK506-binding p

67 Second, we use a recently characterized chimeric receptor composed of rhodopsin and the beta2-ad

68 ith the AChBP, Torpedo californica nAChR and chimeric receptor composed of the alpha7 nAChR extracell

69 A chimeric receptor composed of the extracellular domain o

70 e first, or regulatory, cassette comprises a chimeric receptor composed of the hinge and ligand bindi

71 A chimeric receptor composed of the N-terminal extracellul

72 Here, we generated a chimeric receptor composed of the TrkB extracellular dom

73 y of PC12 cell lines stably transfected with chimeric receptors composed of the extracellular domain

74 C12 cell lines expressing similar amounts of chimeric receptors composed of the extracellular domain

75 hypothesis, we created ligand-regulated TLR chimeric receptors composed of the extracellular region

76 CD8 T cells expressing a chimeric receptor comprising Ly49H extracellular and CD3

77 We show that wild-type Rfz2 and a chimeric receptor consisting of the extracellular and tr

78 M1 failed to induce autophosphorylation of a chimeric receptor consisting of the extracellular domain

79 -15Ralpha cytoplasmic domain, we generated a chimeric receptor consisting of the extracellular domain

80 dimer peptide, but not IL-5, can activate a chimeric receptor consisting of the IL-5Ralpha extracell

81 We observed that cross-linking of a chimeric receptor consisting of the murine CD28 extracel

82 A chimeric receptor construct is utilized to show that cle

83 Using a chimeric receptor construct, we provide evidence that pl

84 Chimeric receptors constructed from receptors with oppos

85 Chimeric receptors, constructed by switching the cytopla

86 in and p75(NTR), we analyzed binding between chimeric receptor constructs and truncated p75(NTR) vari

87 ansmembrane domains to AGRP binding by using chimeric receptor constructs of the human melanocortin-1

88 both receptors, we engineered a series of 14 chimeric receptor constructs, allowing us to determine t

89 these receptors using LRP minireceptors, its chimeric receptor constructs, and full-length VLDLR and

90 ary CD4+ T cells expressing a CD8 alpha/CD28 chimeric receptor containing a mutation at tyrosine 200

91 essed, in bone marrow-derived macrophages, a chimeric receptor containing a range of tyrosine to phen

92 ammaRII(b)(-/-) mice or upon clustering of a chimeric receptor containing CD8 and the immunoreceptor

93 ensitizes signaling mediated by a transduced chimeric receptor containing extracellular domains of pl

94 ionally significant, we transduced EC with a chimeric receptor containing extracellular domains of pl

95 GP Ibalpha was inhibited by co-expressing a chimeric receptor containing interleukin 2 receptor alph

96 in the receptors, individual exoloops of the chimeric receptor containing the ectodomain of the LH re

97 uate potential ligand activators of SmRK1, a chimeric receptor containing the extracellular domain of

98 We recently constructed a chimeric receptor containing the extracellular domain of

99 cient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of

100 s proliferation in vitro and activation of a chimeric receptor containing the TACI intracellular doma

101 T cell lines expressing CD8alpha/28 chimeric receptors containing a mutation in tyrosine 173

102 In this work we show that chimeric receptors containing amino acids 1-1,680 of RyR

103 Only chimeric receptors containing both JAK2 kinase activity

104 in the V3 crown had fusogenic activity with chimeric receptors containing either the N terminus or l

105 To test this hypothesis we expressed chimeric receptors containing fragments of Sstr3 and Htr

106 oped a functional assay utilizing a panel of chimeric receptors containing the extracellular and tran

107 The generation and analysis of chimeric receptors containing the extracellular recognit

108 stoma cells when compared with expression of chimeric receptors containing wild-type gp130 cytoplasmi

109 A chimeric receptor, containing the extracellular domain o

110 We produced mice that express a chimeric receptor, containing the juxtamembrane region o

111 loss of transactivation seen with the mutant chimeric receptor correlated with a decrease in Vav tyro

112 Chimeric receptors created from distant members of the h

113 The chimeric receptor CXP, in which the NT of mCRFR1 was ann

114 Using chimeric receptor DBDs, the higher intrinsic DNA binding

115 s expressing the dileucine-mutated CD28-zeta chimeric receptor demonstrated enhanced proliferation, c

116 compounds for as little as 15 s resulted in chimeric receptor dimerization detectable as beta-gal en

117 tance by transducing CD56+CD3- NK cells with chimeric receptors directed against CD19, a molecule wid

118 The chimeric receptor displayed a pharmacological binding pr

119 eta4 signaling, however, dimerization of the chimeric receptor does not activate either Akt or Erk1/2

120 d neutralization by engineered antibodies or chimeric receptors, downregulation of its expression wit

121 two receptors intact, we, recently developed chimeric receptors (EGDR and EGLT) in which the extracel

122 Using the chimeric-receptor EGLT in which the extracellular domain

123 In this study we constructed a chimeric receptor, EGNP-1, by fusing the extracellular d

124 behind these divergent responses, we made a chimeric receptor (ErbB1/2) composed of the extracellula

125 nstitution experiments demonstrated that the chimeric receptor, even in the phosphorylated state, exi

126 The generation of chimeric receptors exchanging different domains of noncl

127 Chimeric receptor experiments demonstrated that the extr

128 Fluorescence, because of the chimeric receptors expressed, was over the whole oocyte

129 The alpha(FR) chimeric receptor fails to rescue any aspect of the PDGF

130 After endocytosis, the chimeric receptor first enters sorting endosomes, and it

131 differences, we constructed two Flag-tagged chimeric receptors, Flag-h/rkor and Flag-r/hkor, in whic

132 For this purpose we have constructed a chimeric receptor for VEGFR-1 (CTR) and VEGFR-2 (CKR) in

133 ion, a method for tailoring spacer length of chimeric receptors for optimal function, and a functiona

134 nd should prove useful in the development of chimeric receptors for therapeutic purposes.

135 we first studied four loss-of-affinity GRPR chimeric receptors formed by exchanging the four extrace

136 ignaling in a cellular context, a c-fms-Tie1 chimeric receptor (fTie1) was expressed in NIH 3T3 cells

137 ate that inactivation of this motif enhances chimeric receptor function, and illustrate a potential n

138 Nitrite activated the chimeric receptor Gal-ER containing the DNA-binding doma

139 er ex vivo expansion and transduction with a chimeric receptor gene (CD4/CD3-zeta) between identical

140 Examination of chimeric receptors, generated by domain exchange between

141 mary) T cells transduced with tumor-specific chimeric receptor genes can be expanded and maintained l

142 A chimeric receptor, GerU*, demonstrates interchangeabilit

143 However, 32D cells expressing the chimeric receptor had less IL-15-induced proliferation t

144 Moreover, these chimeric receptors had a fast-desensitizing component, e

145 Since studies of chimeric receptors have indicated that the extracellular

146 A chimeric receptor (hGM/beta(c)), comprising the extracel

147 Expression of active Notch1/Notch3 chimeric receptors implicated the RBPjk-association mole

148 ne receptor (nAChR) agonist activity using a chimeric receptor in a functional, cell-based, high-thro

149 By expressing a chimeric receptor in an NK-like cell line, we found that

150 Expression of this chimeric receptor in beta4-null cancer cells enabled us

151 ther than CD28 could be included in a single chimeric receptor in series with TCRzeta to mediate the

152 ptor (TfR/SR-A) resulted in retention of the chimeric receptor in the endoplasmic reticulum suggestin

153 y vaccine-boosting donor cells through their chimeric receptor in vivo.

154 The subsequent testing of a "reverse" chimeric receptor in which sequences encoding transmembr

155 However, a chimeric receptor in which the DD of CD120a was fused to

156 nities are similar to those for binding to a chimeric receptor in which the ECD1 of CRFR2beta replace

157 gain insight into this mechanism, we used a chimeric receptor in which the ligand binding domain of

158 emonstrated by its weakened antagonism for a chimeric receptor in which the membrane-spanning domains

159 An analogous completely foreign chimeric receptor in which the Y440 motif is replaced wi

160 Using full-length and Gal4-LBD chimeric receptors in functional assays, 20:4,n6 induced

161 e homology and equivalent expression by both chimeric receptors in the ventral prostate gland, only F

162 s pharmacological difference, we constructed chimeric receptors in which individual extracellular loo

163 Chimeric receptors in which residues 310-312 were replac

164 CH-8 cells were transfected with CXCR1/CXCR2 chimeric receptors in which the 40-amino acid C-terminal

165 Using chimeric receptors in which the C terminus of PAR(2) is

166 To test this premise, we constructed chimeric receptors in which the extracellular and transm

167 We next studied chimeric receptors in which the pattern of beta-arrestin

168 Experiments with the chimeric receptors indicate that Shc also signals to the

169 ; site-directed mutagenesis in wild-type and chimeric receptors indicated that the threonine residue

170 Use of chimeric receptors indicates that the CSF-1 receptor is

171 Upon arginine vasopressin stimulation, this chimeric receptor induced robust calcium mobilization an

172 The chimeric receptor initiates plant defense responses in r

173 Introduction of EphB1-EphB2 chimeric receptors into RGCs reveals that both extracell

174 The chimeric receptor is unable to amplify growth factor-med

175 We analyzed chimeric receptor kinases by fusing CLV1 and BRASSINOSTE

176 However, chimeric receptors lacking an intact box2 domain of Mpl

177 Chimeric receptor LGR7/8 with the ectodomain from LGR7 b

178 rugs or mutations, or when cells expressed a chimeric receptor likely to have impaired dimerization.

179 We designed a chimeric receptor linking NKG2D, a natural killer (NK) c

180 These chimeric receptors manifest both nuclear translocation a

181 This type of chimeric receptor may now be used to discover the most p

182 Using a chimeric receptor model where the granulocyte/monocyte c

183 Finally, the chimeric receptor-modified CTL ameliorated or blocked ex

184 l, its cytoplasmic zeta-chain stimulates the chimeric receptor-modified T cell (RMTC).

185 We show that 1) chimeric receptor modules built with the ectodomains of

186 stimulates dimerization and activation of a chimeric receptor molecule composed of the extracellular

187 Using chimeric receptors, mutagenesis, and molecular modeling,

188 Using the antibody and point/deletion/chimeric receptor mutants, we demonstrate that changes i

189 for the IFN-gamma-like response through the chimeric receptors, nor does it mediate an IFN-gamma-lik

190 Using a series of deletion mutations and chimeric receptors of p75(NTR) and the related Fas recep

191 en coupled to the green fluorescent protein, chimeric receptors offer a powerful new tool to 1) study

192 required the presence of the tumor-specific chimeric receptor on T cells.

193 rated cell lines that express either EGFR-H2 chimeric receptor or HER2 and HER3 receptors in an EGFR-

194 Using ErbB-2 mutants expressed as chimeric receptors or green fluorescent protein fusion p

195 imulating factor receptor (GCSFR)-gp130(133) chimeric receptor, overexpression of Stat3 induced gamma

196 The reciprocal chimeric receptor (P1-NP2) was not activated by TIP39 an

197 with their PTH1R counterparts resulted in a chimeric receptor, PEC, which had normal CRFR1 functiona

198 An epidermal growth factor receptor/gp130 chimeric receptor previously shown by us to transactivat

199 elium is rescued by an exogenously expressed chimeric receptor (prl-EpoR) containing the PrlR extrace

200 rly, TCR transgenic CD8 cells expressing the chimeric receptor produced higher effector numbers durin

201 CD8 T cells expressing the chimeric receptor protect mice in vivo from lethality in

202 st a functionally unimportant component of a chimeric receptor protein.

203 s using the EIAV SU gp90 protein and various chimeric receptor proteins derived from exchanges betwee

204 transduction by the gamma-like chains using chimeric receptor proteins.

205 ng T cells to attack cancer using engineered chimeric receptors provides powerful new therapeutic cap

206 Chimeric receptors providing B7 and TNFR family costimul

207 constitutively activated RARalpha or RARbeta chimeric receptors (RARVP16) in branching airways of tra

208 lar loop (E3) in the rat BRS-3 resulted in a chimeric receptor (RB3-E3) that behaved almost identical

209 reporter cells expressing a CD3zeta-NKR-P1A chimeric receptor; reciprocally, reporter cells with a C

210 modification of alloreactive T cells with a chimeric receptor recognizing folate-binding protein, an

211 Expression of this chimeric receptor reduced hippocampal lesion size after

212 By using the Gal4 chimeric receptor/reporter cotransfection system, the li

213 Expression of this chimeric receptor restores presynaptic and postsynaptic

214 Mice expressing the chimeric receptor retain a severe bleeding phenotype, co

215 tory function in a single receptor maximizes chimeric receptor sensitivity and potency.

216 Analysis of FGF8 and FGF9 binding to chimeric receptors showed that a broad region spanning I

217 Primary T cells expressing chimeric receptors specific for tumor or viral antigens

218 Next, using a chimeric receptor strategy, we found that two independen

219 This was shown by chimeric receptor studies in recombinant cell line assay

220 Chimeric receptor studies support the importance of this

221 In addition, through chimeric receptor studies, we determined that the second

222 g a set of alpha7-5-hydroxytryptamine type 3 chimeric receptor subunit cDNAs, we expressed these cons

223 Chimeric receptor subunits and site-directed mutants wer

224 replaced with the I domain of alpha(M), the chimeric receptor supported cell migration to Fg; howeve

225 Inactivation of this motif increased chimeric receptor surface expression 2- to 5-fold.

226 ly, we used an erythropoietin (EPO) receptor chimeric receptor system in which IL-2-dependent HT-2 T

227 h these two receptors intact, we developed a chimeric receptor system in which the N terminus of the

228 T-cell precursors transduced to express a chimeric receptor targeting hCD19 resulted in significan

229 ns to activate the TCR or a CD8alpha/CD3zeta chimeric receptor (termed CD8zeta).

230 Importantly, expression of a chimeric receptor that consisted of the extracytoplasmic

231 xpression of transgenic wild-type IL-7R or a chimeric receptor that consisted of the extracytoplasmic

232 s of IL-2 from PBT than a similar transduced chimeric receptor that contains a wild-type CD28 CYT.

233 First, Argos is unable to inhibit a chimeric receptor that contains an extracellular domain

234 nically expressed on T cells a heterodimeric chimeric receptor that genetically links an autoantigeni

235 orming growth factor beta (TGF-beta) R2-41BB chimeric receptor that improved solid tumor clearance.

236 m and TMB-8 had much higher affinity for the chimeric receptor that included the M(2) second outer lo

237 The cells are engineered with a cell-surface chimeric receptor that presents the nonmammalian enzyme

238 with that of the rP2Y(4) receptor yielded a chimeric receptor that was activated fully by UTP and ne

239 quirement for Wnt ligand can be abrogated by chimeric receptors that allow formation of Frizzled-LRP

240 embrane domains 4 or 6, however, resulted in chimeric receptors that displayed no detectable 2-[(125)

241 ocket was obtained in signaling studies with chimeric receptors that exhibited improved responses to

242 Chimeric receptors that include CD28 signaling in series

243 ors, we constructed a series of single-chain chimeric receptors that incorporate extracellular human

244 atory cells are transgenically modified with chimeric receptors that link antigen-major histocompatib

245 These modified T cells express chimeric receptors that link ligand recognition and sign

246 When coexpressed with dIRS in COS-7 cells, a chimeric receptor (the extracellular domain of human IR

247 ons of TM4 and TM5 than for any of the other chimeric receptors (the affinities of which remained sim

248 These chimeric receptors then were used in binding and entry a

249 one of the alphav subunit did not enable the chimeric receptor to bind alphaIIbbeta3-specific ligands

250 Here we use chimeric receptors to address the mechanisms of PIR-A si

251 We constructed chimeric receptors to dissect the role of the transmembr

252 developed a cellular immunotherapy that uses chimeric receptors to selectively redirect therapeutic T

253 We also demonstrate that two chimeric receptors, Torextracellular-Egfrcytoplasmic and

254 In response to IL-2 binding, this chimeric receptor transduces IL-4-specific signals and d

255 Several chimeric receptor transgene constructs where domains of

256 IA was exacerbated in IL-2R beta/IL-4R alpha chimeric receptor transgenic mice, with increased diseas

257 us, CD8 and CD4 T cells transduced with this chimeric receptor underwent an enhanced proliferative re

258 Upon IL-8 activation, the chimeric receptors underwent receptor phosphorylation an

259 Activation of the chimeric receptor upon the addition of M-CSF readily med

260 rosine was efficiently phosphorylated in the chimeric receptor upon treating the cells with pervanada

261 The pattern of phenotype rescue by the chimeric receptors used in this study supports a model w

262 or-related receptor 1 (VRR1) by generating a chimeric receptor, V1a/VRR1.

263 We constructed a chimeric receptor (VEGFR2Fas) combining the extracellula

264 Our results indicate that each chimeric receptor was expressed at the cell surface and

265 Furthermore, the chimeric receptor was internalized and recycled at rates

266 However, the chimeric receptor was still capable of binding to a RGD

267 This chimeric receptor was used to conduct an innovative frag

268 for the ALV-J receptor activity, a series of chimeric receptors was created by exchanging the extrace

269 The dose response of chimeric receptors was ligand specific.

270 Using a series of chimeric receptors, we demonstrated that this ligand act

271 Using chimeric receptors, we mapped the region for this differ

272 Transgenic animals expressing a chimeric receptor were generated and bred into the murin

273 interleukin-3-dependent cell line Ba/F3, the chimeric receptors were appropriately expressed on the c

274 Chimeric receptors were constructed in which the cytopla

275 address this, alpha(2A)/alpha(2C) third loop chimeric receptors were constructed.

276 Finally, chimeric receptors were engineered containing the extrac

277 ical residues, site-directed mutagenesis and chimeric receptors were evaluated in functional calcium

278 These chimeric receptors were expressed in hamster cells.

279 hese three ligands for the two related LGRs, chimeric receptors were generated to elucidate the mecha

280 Human CD33-specific chimeric receptors were generated with CD28, inducible c

281 The chimeric receptors were mostly M(5) sequence; the amount

282 virus receptor interaction on infection, two chimeric receptors were prepared which contained antibod

283 To test this hypothesis, chimeric receptors were required in which the cytoplasmi

284 From this library, 80 chimeric receptors were tested against 26 odorants after

285 Chimeric receptors were used to reconstitute development

286 ally, proline recognition was conferred to a chimeric receptor when TM regions associated with the pu

287 However, chimeric receptors, which are composed of combinations o

288 Modulating the signaling characteristics of chimeric receptors will be important for their applicati

289 Third, a retroviral transduced chimeric receptor with a CD28 CYT that is specifically u

290 Long-term treatment of cells expressing the chimeric receptor with agonists, antagonists, and invers

291 ation of neurons transfected with a Met-Robo chimeric receptor with Hepatocyte growth factor leads to

292 created by engineering T cells to express a chimeric receptor with high affinity for human mesotheli

293 in parallel sets of mice as IgM, IgG1, or a chimeric receptor with IgM extracellular domains and tra

294 We constructed a chimeric receptor with the ligand-binding and transmembr

295 to CXCR4; the CCL5 ligand of CCR5 binds the chimeric receptor with ~20x lower affinity.

296 Chimeric receptors with the ectodomain and exoloop 2, bu

297 Chimeric receptors with the hCaR VFT and mGluR1 seven-tr

298 We constructed functional, chimeric receptors with the ligand-binding and transmemb

299 Using chimeric receptors with wild-type and mutant Ig alpha cy

300 FcR vs NKG2D-DAP10) or ectopically expressed chimeric receptors (with ITAM-containing cytoplasmic tai